Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity,Immunity

当前位置： X-MOL 学术 › Immunity › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
Immunity ( IF 25.5 ) Pub Date : 2020-10-14 , DOI: 10.1016/j.immuni.2020.10.004
Tyler J Ripperger ₁ , Jennifer L Uhrlaub ₂ , Makiko Watanabe ₂ , Rachel Wong ₃ , Yvonne Castaneda ₂ , Hannah A Pizzato ₃ , Mallory R Thompson ₄ , Christine Bradshaw ₂ , Craig C Weinkauf ₅ , Christian Bime ₆ , Heidi L Erickson ₆ , Kenneth Knox ₇ , Billie Bixby ₆ , Sairam Parthasarathy ₆ , Sachin Chaudhary ₆ , Bhupinder Natt ₆ , Elaine Cristan ₆ , Tammer El Aini ₆ , Franz Rischard ₆ , Janet Campion ₆ , Madhav Chopra ₆ , Michael Insel ₆ , Afshin Sam ₆ , James L Knepler ₆ , Andrew P Capaldi ₈ , Catherine M Spier ₉ , Michael D Dake ₁₀ , Taylor Edwards ₁₁ , Matthew E Kaplan ₁₂ , Serena Jain Scott ₁₃ , Cameron Hypes ₁₄ , Jarrod Mosier ₁₄ , David T Harris ₁₅ , Bonnie J LaFleur ₁₆ , Ryan Sprissler ₁₇ , Janko Nikolich-Žugich ₁₈ , Deepta Bhattacharya ₁₉

Affiliation

Department of Immunobiology, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Department of Immunobiology, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; University of Arizona Center on Aging, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Department of Immunobiology, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; Division of Biological and Biomedical Sciences, Washington University, St. Louis, MO, USA.
Department of Surgery, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Department of Surgery, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; Department of Medicine, University of Arizona, Phoenix, Phoenix, AZ, USA.
Department of Molecular and Cellular Biology, University of Arizona, Tucson, Tucson, AZ, USA; Functional Genomics Core, University of Arizona, Tucson, AZ, USA.
Department of Pathology, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Office of the Senior Vice-President for Health Sciences, University of Arizona, Tucson, AZ, USA.
University of Arizona Genomics Core and the Arizona Research Labs, University of Arizona Genetics Core, University of Arizona, Tucson, AZ, USA.
Functional Genomics Core, University of Arizona, Tucson, AZ, USA.
Division of Geriatrics, General Medicine and Palliative Care, Department of Medicine, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; Department of Emergency Medicine, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA.
Department of Immunobiology, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; University of Arizona Health Sciences Biobank, University of Arizona, Tucson, AZ, USA.
BIO5 Institute, University of Arizona, Tucson, AZ, USA.
University of Arizona Genomics Core and the Arizona Research Labs, University of Arizona Genetics Core, University of Arizona, Tucson, AZ, USA; BIO5 Institute, University of Arizona, Tucson, AZ, USA.
Department of Immunobiology, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; University of Arizona Center on Aging, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; BIO5 Institute, University of Arizona, Tucson, AZ, USA.
Department of Immunobiology, University of Arizona College of Medicine, Tucson, Tucson, AZ, USA; BIO5 Institute, University of Arizona, Tucson, AZ, USA.

We conducted a serological study to define correlates of immunity against SARS-CoV-2. Compared to those with mild coronavirus disease 2019 (COVID-19) cases, individuals with severe disease exhibited elevated virus-neutralizing titers and antibodies against the nucleocapsid (N) and the receptor binding domain (RBD) of the spike protein. Age and sex played lesser roles. All cases, including asymptomatic individuals, seroconverted by 2 weeks after PCR confirmation. Spike RBD and S2 and neutralizing antibodies remained detectable through 5–7 months after onset, whereas α-N titers diminished. Testing 5,882 members of the local community revealed only 1 sample with seroreactivity to both RBD and S2 that lacked neutralizing antibodies. This fidelity could not be achieved with either RBD or S2 alone. Thus, inclusion of multiple independent assays improved the accuracy of antibody tests in low-seroprevalence communities and revealed differences in antibody kinetics depending on the antigen. We conclude that neutralizing antibodies are stably produced for at least 5–7 months after SARS-CoV-2 infection.

中文翻译：

正交 SARS-CoV-2 血清学检测能够对低流行社区进行监测并揭示持久的体液免疫

我们进行了一项血清学研究，以确定 SARS-CoV-2 免疫力的相关性。与 2019 年冠状病毒病 (COVID-19) 轻度病例相比，患有严重疾病的个体表现出较高的病毒中和滴度以及针对核衣壳 (N) 和刺突蛋白受体结合域 (RBD) 的抗体。年龄和性别的作用较小。所有病例，包括无症状个体，均在 PCR 确认后 2 周内实现血清转化。发病后 5-7 个月内，尖峰 RBD 和 S2 以及中和抗体仍可检测到，而 α-N 滴度下降。对当地社区的 5,882 名成员进行的检测显示，只有 1 个样本对 RBD 和 S2 均具有血清反应性，但缺乏中和抗体。单独使用 RBD 或 S2 无法实现这种保真度。因此，纳入多个独立测定提高了低血清流行率社区中抗体测试的准确性，并揭示了取决于抗原的抗体动力学差异。我们的结论是，中和抗体在 SARS-CoV-2 感染后至少 5-7 个月内稳定产生。

更新日期：2020-11-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11